

REMARKS

Applicants gratefully acknowledge the allowance of claims 1-5, 16, 17 and 21 in the office action dated June 3, 2008.

Amendments To The Claims

Claims 12, 14 and 20 have been canceled without waiver or prejudice to pursuing the subject matter of those claims in a continuing application(s). Claims 6 and 18 have been amended by deletion of the phrase "bone defect, occurring individually or together, or" from those claims. Claim 13 has been amended by making it depend from claim 6 rather than claim 12. Support for these amendments is in the specification as filed, including the original claims.

No new matter has been added by these amendments. Applicants reserve the right to file divisional or continuation applications, as appropriate, directed to the non-elected, canceled and deleted subject matter of this invention.

The 35 U.S.C. §112, first paragraph Rejection

Claims 6-8, 12-14, 18 and 20 have been rejected under 35 U.S.C. §112, first paragraph as allegedly not being enabled such that one skilled in the art could carry out the invention. Claims 12, 14 and 20 have been canceled by this amendment and thus the instant rejection of those claims is moot. The Examiner has admitted that the specification is enabling with respect to the treatment of bone fracture or the promotion of bone in-growth with compounds of examples 1-37 of formula (I) (see page 6, second paragraph of Office Action dated June 3, 2008).

The scope of claims 6-8, 13 and 18 has been restricted to methods of treating bone fracture or promoting bone in-growth using compounds of formula (I). The claims have been limited to subject matter related to that which the Examiner has acknowledged is enabled. Applicants respectfully submit that one skilled in the art could readily practice the method of claims 6-8, 13 and 18 without undue experimentation. Applicants have provided guidance with respect to dosages of compounds of Formula I to be employed in the methods of treatment at page 8, lines 8-18 of the specification. Dosage forms and methods of administering the compounds of Formula I have been provided at page 12, line 1 through page 19, line 10 of the specification. *In vitro* PDE2 inhibition data for the compounds of Formula I has been provided at page 38, line 23 through page 40, line 2 of the specification.

An *in vivo* bone fracture model and resulting data has been provided at page 40, line 3 through page 41, line 3 of the specification. An *in vivo* periosteal injection model and resulting bone mineral content data has been provided at page 41, lines 4-26 of the specification. Applicants respectfully submit that the claims, as amended, are fully enabled such that one skilled in the art could readily practice the invention. One skilled in the art, in view of the direction and guidance provided in the specification and in view of the *in vitro* and *in vivo* results provided would readily be able to practice the claimed methods of treatment without undue experimentation. Applicants respectfully request that the Examiner reconsider claims 6-8, 13 and 18, in view of the foregoing amendments and remarks, and withdraw the 35 U.S.C. §112, first paragraph rejection.

Entry of the foregoing amendments to the claims and consideration of the foregoing remarks is respectfully requested. An early and favorable response is respectfully solicited.

Respectfully submitted,

Date: 11 September 2008
Pfizer Inc.
Patent Department
Eastern Point Road, MS 8260-1611
Groton, Connecticut 06340
(860) 715-6645

/ John A. Wichtowski /
John A. Wichtowski
Attorney for Applicant(s)
Reg. No. 48,032